Cargando…

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

Castrate-resistant prostate cancer (CRPC) is a disease where survival is poor and treatment is challenging. Over the past 3 years, significant advances in the field have been made with US Food and Drug Administration approval of new drugs for patients with CRPC. However, despite the presence of new...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neha, Al Ustwani, Omar, Shen, Li, Pili, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928061/
https://www.ncbi.nlm.nih.gov/pubmed/24600234
http://dx.doi.org/10.2147/OTT.S53524